	US 12,152,063 B2
	Insulin analogues and uses thereof
Frantisek Hubalek, Herlev (DK); Mathias Norrman, Staffanstorp (SE); Helle Birk Olsen, Alleroed (DK); Peter Madsen, Bagsvaerd (DK); Thomas Boerglum Kjeldsen, Virum (DK); and Jeppe Sturis, Vaerloese (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Oct. 6, 2022, as Appl. No. 17/961,438.
Application 17/961,438 is a continuation of application No. 17/117,263, filed on Dec. 10, 2020, granted, now 11,498,951.
Claims priority of application No. 19215315 (EP), filed on Dec. 11, 2019.
Prior Publication US 2023/0192801 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/62 (2006.01); A61K 47/22 (2006.01); A61P 3/10 (2006.01)

CPC C07K 14/62 (2013.01) [A61K 47/22 (2013.01); A61P 3/10 (2018.01)]

17 Claims

1. A pharmaceutical composition, comprising:

0.6 mM to 3.6 mM of human insulin analogue A9E, B3E, B26E, desB30;

1. 5 mg/ml or 1.79 mg/ml phenol;

1.72 mg/ml or 2.05 mg/ml m-cresol;

0 mM to 250 mM glycerol;

0 0.1 mM to 20 mM phosphate buffer;

0 mM to 200 mM nicotinamide;

0 mM to 20 mM citrate;

optionally, pharmaceutically acceptable excipients; and

pH of 7.2-7.8.